niraparib and abiraterone acetate (Akeega): FDA status

Approved Approved Dec 12, 2025. Indication: BRCA2 mutated metastatic castration sensitive prostate cancer. Company: Johnson and Johnson.

Regulatory history

All products in the FDA Tracker

Loading today's edition…